Cardiovascular

FDA denies claims for Zetia, Vytorin

February 17, 2016

FDA declined to approve Merck’s claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease.

FDA: Slightly elevated risk of cardiovascular, cerebrovascular issues with Xolair

September 29, 2014

An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug omalizumab (Xolair, Genentech) than in those who were not treated with omalizumab. As a result, FDA has added information about these potential risks to the drug label.

[BLOG] The acute coronary syndrome pipeline: Novel therapies targeting unmet needs in niche patient populations

August 19, 2014

Not surprisingly, the treatment costs associated with ACS and its various comorbidities are astoundingly high.

ADA: Canola oil can help control blood glucose in people with type 2 diabetes

June 17, 2014

Unhydrogenated, unsaturated vegetable oils, such as canola oil, can have health advantages when included in as part of a low-glycemic index (GI) diet in people with type 2 diabetes, according to research presented at American Diabetes Association Scientific Sessions in San Francisco, and published in Diabetes Care.

Novartis heart failure drug fails to win FDA approval

May 19, 2014

FDA has decided not to approve acute heart failure drug serelaxin (Novartis).

FDA approves Pradaxa for treatment, reduction in risk of recurrence of DVT, PE

April 09, 2014

FDA approved dabigatran etexilate mesylate (Pradaxa, Boehringer Ingelheim Pharmaceuticals) for treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5 to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated.

ACC: Bivalirudin associated with reductions in cardiac death, major bleeding in STEMI patients undergoing PCI

April 03, 2014

Compared to a combination of heparin and a glycoprotein (GP) IIb/IIIa inhibitor, use of bivalirudin (Angiomax) is associated with significant absolute reductions in risk for cardiac death and major non-coronary artery bypass graft (CABG) bleeding, according to data presented at the American College of Cardiology 63rd Annual Scientific Session (ACC.14), in Washington, D.C.